Aktuellt
SENASTE
Redeye comments on Cereno’s Q4 2021 report, concluding a year in which the company has made several investments that will hopefully start bearing fruit in 2022 and beyond. We judge the company is entering a critical period, with phase II top-line data from its trial with CS1 in PAH expected towards year-end 2022. Further, TO2 exercise awaits in September, likely securing funding to continue clinical development of CS1 and drive Cereno’s preclinical pipeline forward.
LÄS MER
